ELI LILLY/ US5324571083 /
2024-09-03 8:38:49 PM | Chg. +0.100 | Volume | Bid8:42:02 PM | Ask8:42:02 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
867.800EUR | +0.01% | 4,687 Turnover: 4.08 mill. |
867.200Bid Size: 100 | 869.800Ask Size: 100 | 823.2 bill.EUR | - | - |
Newsfile Corp
08-28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
08-27
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-14
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
08-14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08-08
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-06
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
08-06
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
08-02
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-01
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
08-01
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives